Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

BioArctic AB (publ) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy ...

The prescribing information for Leqembi approved by the FDA includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class, and the two ...

It is a monoclonal antibody (mAb) that selectively targets ... The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and ...

One key factor, however, is that anti-pyroglutamate amyloid antibodies seem to reduce the risk of neuroinflammation – potentially reducing side effects that have been seen with Leqembi and ...

In 2024, drugmakers delivered breakthrough treatments in conditions that had seen little progress for decades—and helped make existing therapies more accessible. Approved in July, Eli Lilly’s ...

“Acumen is focused on developing therapeutics for people living with Alzheimer’s disease. We are advancing sabirnetug, which is a monoclonal antibody that was designed to target amyloid beta oligomers ...